What pleased me was that there is no further extension to the work with Lilly and they are now discussing a licence agreement. Nothing negative about that.
So we have sold a jewel which BRH controlled for shares and warrants in a company BRH does not control. No wonder RMS shares rose and ours did not. Not at all convinced of the vaue of the deal to BRH.
iOctura in Switzerland have announced raising of €20 million to finance research anddevelopment of drugs which link cancer and fibrosis. Im not a scientist so best research.
iOctura in Switzerland have announced raising of €20 million to finance research anddevelopment of drugs which link cancer and fibrosis. Im not a scientist so best research.
Euclid.. do we really know we have to wait.until November? I know the project has a deadline of December but could not Pharm2farm not be working for an earlier end?
Tomvisual i was referring to the CEO' s dealing in shares not so long ago and subsequent bailing out of RMS. The sp dived. I agree with Pegasus, the valuation of the investments is hard to understand. Imho
I dont think you should complain about the interest rate. A loan of this size secured only by intra group guarantees for a still young company..not bad.